Andrea M Seet

TL;DR: In this article, the authors investigated baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).

TL;DR: In this paper, the authors investigated factors associated with COVID-19 outcomes in patients with primary systemic vasculitis or polymyalgia rheumatica, and found that patients with these conditions are at high risk for poor COVID19 outcomes due to the treatments used, the potential organ damage caused by primary systemic Vasculitis, and the demographic factors associated associated with the conditions.

TL;DR: In this paper, the authors performed a retrospective cohort study using national Veterans Affairs Health Care System data for individuals who tested positive for SARS-CoV-2 and found no significant association between rheumatic disease and hospitalization or death.

TL;DR: Black and Hispanic individuals with SLE experienced more severe COVID-19 outcomes, which is consistent with findings in the US general population, and suggest that more aggressive efforts are needed to prevent and treat infection in this population.